How long does the efficacy of Platinib (Pujihua) remain stable when treating diseases?

Pralsetinib is a selective RET tyrosine kinase inhibitor mainly used to treat RET fusion-positive non-small cell lung cancer (NSCLC), thyroid cancer and other related solid tumors. By inhibiting the RET signaling pathway, Platinib can effectively block tumor cell proliferation and survival, thereby achieving tumor growth control. Clinical trials have shown that platinib has significant anti-tumor activity in RET fusion-positive patients.

According to clinical study data, platinib can achieve longer-term disease control in most patients. In first-line or multi-line treatment, the objective response rate (ORR) of patients is as high as 60%~70%, and the response of some patients can be maintained for more than 12 months. The persistence of the drug effect is related to the patient's tumor type, previous treatment history, RET fusion subtype and other factors, but the overall efficacy curve is relatively stable.

In long-term follow-up, the efficacy of platinib usually lasts from several months to more than a year. Even if some patients experience mild disease progression during continued oral treatment, dose adjustment or combination therapy can extend the stable period of efficacy. The study also showed that for patients with RET fusion-positive thyroid cancer, the median progression-free survival (PFS) of platinib can reach 17 to 20 months, indicating that it has a longer stable period in specific groups of people.

In order to maintain the stable efficacy of platinib, patients should strictly follow the doctor's instructions to take it daily, conduct regular imaging evaluation and laboratory monitoring, and detect disease progression or adverse reactions in a timely manner. For patients whose efficacy declines or who show signs of drug resistance, the treatment plan can be adjusted under the guidance of a doctor or combined with other targeted drugs. In addition, ongoing follow-up and monitoring help maximize the long-term efficacy of the drug and ensure treatment safety.

Reference link:https://www.drugs.com